Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 11/2014

01-11-2014 | Nuclear Medicine

Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis

Authors: Liping Fu, Linwen Liu, Jinming Zhang, Baixuan Xu, Yong Fan, Jiahe Tian

Published in: European Radiology | Issue 11/2014

Login to get access

Abstract

Objectives

To identify the optimal time window for capturing perfusion information from early 11C-PIB imaging frames (perfusion PIB, 11C-pPIB) and to compare the performance of 18F-FDG PET and "dual biomarker" 11C-PIB PET [11C-pPIB and amyloid PIB (11C-aPIB)] for classification of AD, MCI and CN subjects.

Methods

Forty subjects (14 CN, 12 MCI and 14 AD patients) underwent 18F-FDG and 11C-PIB PET studies. Pearson correlation between the 18F-FDG image and sum of early 11C-PIB frames was maximised to identify the optimal time window for 11C-pPIB. The classification power of imaging parameters was evaluated with a leave-one-out validation.

Results

A 7-min time window yielded the highest correlation between 18F-FDG and 11C-pPIB. 11C-pPIB and 18F-FDG images shared a similar radioactive distribution pattern. 18F-FDG performed better than 11C-pPIB for the classification of both AD vs. CN and MCI vs. CN. 11C-pPIB + 11C-aPIB and 18F-FDG + 11C-aPIB yielded the highest classification accuracy for the classification of AD vs. CN, and 18F-FDG + 11C-aPIB had the best classification performance for the classification of MCI vs. CN.

Conclusion

C-pPIB could serve as a useful biomarker of rCBF for measuring neural activity and improve the diagnostic power of PET for AD in conjunction with 11C-aPIB. 18F-FDG and 11C-PIB dual-tracer PET examination could better detect MCI.

Key Points

• Dual-tracer PET examination provides neurofunctional and neuropathological information for AD diagnosis.
• The identified optimal 11C-pPIB time frames had highest correlation with 18F-FDG.
• 11C-pPIB images shared a similar radioactive distribution pattern with 18F-FDG images.
• 11C-pPIB can provide neurofunctional information.
• Dual-tracer PET examination could better detect MCI.
Literature
1.
Engler H, Forsberg A, Almkvist O et al (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129:2856–2866PubMedCrossRef
2.
Kadir A, Almkvist O, Forsberg A et al (2012) Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 33(198):e191–114
3.
Bacskai BJ, Hickey GA, Skoch J et al (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 100:12462–12467PubMedCrossRefPubMedCentral
4.
Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:1630–1645PubMedCrossRefPubMedCentral
5.
Klunk WE, Wang Y, Huang GF et al (2003) The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086–2092PubMed
6.
Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55:306–319PubMedCrossRef
7.
Mintun MA, Larossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452PubMedCrossRef
8.
Rabinovici GD, Furst AJ, O'Neil JP et al (2007) 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68:1205–1212PubMedCrossRef
9.
10.
Buongiorno M, Compta Y, Marti MJ (2011) Amyloid-beta and tau biomarkers in Parkinson’s disease-dementia. J Neurol Sci 310:25–30PubMedCrossRef
11.
Morris JC, Roe CM, Xiong C et al (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122–131PubMedCrossRefPubMedCentral
12.
Rowe CC, Ng S, Ackermann U et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718–1725PubMedCrossRef
13.
Koeppe RA, Gilman S, Joshi A et al (2005) 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 46:936–944PubMed
14.
Van Laere K, Clerinx K, D'Hondt E, de Groot T, Vandenberghe W (2010) Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 51:588–595PubMedCrossRef
15.
Blomquist G, Engler H, Nordberg A et al (2008) Unidirectional Influx and Net Accumulation of PIB. Open Neuroimaging J 2:114–125CrossRef
16.
Price JC, Klunk WE, Lopresti BJ et al (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 25:1528–1547PubMedCrossRef
17.
Wu Y, Carson RE (2002) Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 22:1440–1452PubMedCrossRef
18.
Forsberg A, Engler H, Blomquist G, Langstrom B, Nordberg A (2012) The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta 1822:380–385PubMedCrossRef
19.
Rostomian AH, Madison C, Rabinovici GD, Jagust WJ (2011) Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med 52:173–179PubMedPubMedCentral
20.
Yesavage JA, Brink TL, Rose TL et al (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49PubMedCrossRef
21.
Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414PubMedCrossRef
22.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308PubMedCrossRef
23.
Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270–279PubMedCrossRefPubMedCentral
24.
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263–269PubMedCrossRefPubMedCentral
25.
Philippe C, Haeusler D, Mitterhauser M et al (2011) Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C] methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB). Appl Radiat Isot 69:1212–1217
26.
27.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D et al (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289PubMedCrossRef
28.
Devanand DP, Mikhno A, Pelton GH et al (2010) Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 23:185–198PubMedCrossRefPubMedCentral
29.
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42:85–94PubMedCrossRef
30.
Silverman DH, Small GW, Chang CY et al (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120–2127PubMedCrossRef
31.
Genovese CR, Lazar NA, Nichols T (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15:870–878PubMedCrossRef
32.
Mazziotta JC, Phelps ME (1986) Positron emission tomography studies of the brain. In: Phelps ME, Mazziotta JC, Schelbert H (eds) Positron emission tomography & autoradiography: principles & applications for the brain & heart. Raven, New York, pp 493–579
33.
Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32:486–510PubMedCrossRef
34.
Desgranges B, Baron JC, de la Sayette V et al (1998) The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 121(Pt 4):611–631PubMedCrossRef
35.
Haxby JV, Grady CL, Koss E et al (1990) Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 47:753–760PubMedCrossRef
36.
Sokoloff L (1981) Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc 40:2311–2316PubMed
37.
Frackowiak RS, Pozzilli C, Legg NJ et al (1981) Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104:753–778PubMedCrossRef
38.
Nihashi T, Yatsuya H, Hayasaka K et al (2007) Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat Med 25:255–262PubMedCrossRef
39.
40.
Fan Y, Batmanghelich N, Clark CM, Davatzikos C, Alzheimer's Disease Neuroimaging I (2008) Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage 39:1731–1743PubMedCrossRefPubMedCentral
41.
Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465PubMedCrossRef
42.
Kemppainen NM, Aalto S, Wilson IA et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603–1606PubMedCrossRef
43.
Lopresti BJ, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972PubMed
44.
Pike KE, Savage G, Villemagne VL et al (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130:2837–2844PubMedCrossRef
45.
Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ (2010) Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20:843–854PubMedPubMedCentral
46.
47.
Jack CR Jr, Lowe VJ, Senjem ML et al (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131:665–680PubMedCrossRefPubMedCentral
48.
Jack CR Jr, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:257–262PubMedCrossRefPubMedCentral
Metadata
Title
Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis
Authors
Liping Fu
Linwen Liu
Jinming Zhang
Baixuan Xu
Yong Fan
Jiahe Tian
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 11/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3311-x

Other articles of this Issue 11/2014

European Radiology 11/2014 Go to the issue

Magnetic Resonance

Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Forensic Medicine

Post-mortem cardiac diffusion tensor imaging: detection of myocardial infarction and remodeling of myofiber architecture

Cardiac

Left atrial dysfunction in type 2 diabetes mellitus: insights from cardiac MRI

Magnetic Resonance

Focal hemodynamic patterns of status epilepticus detected by susceptibility weighted imaging (SWI)

Oncology

Toward clinically usable CAD for lung cancer screening with computed tomography

Neuro

1H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery